A cross-sectional study of 28 patients with PMO, 32 with postmenopausal osteopenia and 30 healthy control subjects (postmenopausal non-osteoporosis) found that significantly higher levels of FGF-23 in the PMO group compared to the postmenopausal osteopenia and control groups (50). The gene discussed is FGF23; the disease is Osteopenia.